Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 89

Sort by

Sort Order Select

Journal Articles

A randomized study of conventional chemotherapy +/- uproleselan in older adults with Acute Myeloid Leukemia eceiving intensive induction chemotherapy (Alliance A041701)

Blood (2025) 146 (Supplement 1): 3415.

https://doi.org/10.1182/blood-2025-3415

Published: 2025

Journal Articles

A multicenter real-world study on response and survival in older patients with acute myeloid leukemia treated with intensive chemotherapy versus VEN/HMA by 2022 and 2024 ELN risk stratifications: An analysis from the MARROW consortium

Blood (2025) 146 (Supplement 1): 5157.

https://doi.org/10.1182/blood-2025-5157

Published: 2025

Journal Articles

Characteristics and clinical outcomes of patients (pts) with Acute Myeloid Leukemia (AML) with Mecom rearrangements: An analysis from the MARROW consortium

Blood (2025) 146 (Supplement 1): 294.

https://doi.org/10.1182/blood-2025-294

Published: 2025

Journal Articles

Defining the clinical characteristics and outcomes of adult patients (pts) with 11q23/KMT2A-rearranged Acute Myeloid Leukemia (AML): An analysis from the MARROW consortium

Blood (2025) 146 (Supplement 1): 292.

https://doi.org/10.1182/blood-2025-292

Published: 2025

Journal Articles

Accounting for long-term survivors and population-expected survival improves survival outcomes estimation and prediction in older patients with core-binding factor (CBF) Acute Myeloid Leukemia (AML)

Justice Ameyi, Deedra Nicolet, Michael Walker, Krzysztof Mrózek, Ann-Kathrin Eisfeld, Kellie Archer

Blood (2025) 146 (Supplement 1): 2584.

https://doi.org/10.1182/blood-2025-2584

Published: 2025

Journal Articles

Loss of the Y chromosome defines a biologically distinct subtype of Acute Myeloid Leukemia (AML), associated with decreased inflammatory response patterns, and favorable outcomes in young male patients (pts)

Blood (2025) 146 (Supplement 1): 1723.

https://doi.org/10.1182/blood-2025-1723

Published: 2025

Journal Articles

Tri-partied analyses define clinical outcomes and molecular features of patients (pts) with acute promyelocytic leukemia (APL)

Blood (2025) 146 (Supplement 1): 8183.

https://doi.org/10.1182/blood-2025-8183

Published: 2025

Journal Articles

Treatment responses and survival of newly diagnosed older or unfit patients (pts) with IDH1/2-mutated Acute Myeloid Leukemia (AML): An analysis of the MARROW consortium

Blood (2025) 146 (Supplement 1): 1626.

https://doi.org/10.1182/blood-2025-1626

Published: 2025

Journal Articles

Characterization of Sole Loss of the Y Chromosome and Associated Effects on Adaptive Immunity in Adult Male Patients with Acute Myeloid Leukemia (AML)

Maria Velegraki, Cankun Wang, Deedra Nicolet, Krzysztof Mrózek, Payton Weltge, Ethan Hamp, Jill Buss, Andrea Laganson, Christopher C. Oakes, Jordan Krull, John C. Byrd, Richard M. Stone, Qin Ma, Ann-Kathrin Eisfeld, Zihai Li

Blood (2024) 144 (Supplement 1): 4304.

https://doi.org/10.1182/blood-2024-211437

Published: 2024

Journal Articles

Real World Outcomes of Patients (Pts) with Acute Myeloid Leukemia, Myelodysplasia-Related (AML-MR) or Therapy-Related AML (t-AML) Receiving Venetoclax-Based Therapies

Kelly Pugh, Michael C Walker, Deedra Nicolet, Victoria Klein, Krzysztof Mrózek, Gregory K Behbehani, James S. Blachly, Uma Borate, Nicole R. Grieselhuber, Kristin L Koenig, Karilyn T. Larkin, Meixiao Long, Andrew Srisuwananukorn, Ann-Kathrin Eisfeld, Alice Mims

Blood (2024) 144 (Supplement 1): 7929.

https://doi.org/10.1182/blood-2024-210135

Published: 2024

Journal Articles

Impact of Socioeconomic Factors on Survival for Adolescent and Young Adult (AYA) Patients (Pts) with Acute Myeloid Leukemia

Andrea Laganson, Victoria Klein, Deedra Nicolet, Aadarsh Teli, Krzysztof Mrózek, Jacob Wareti, Michael C Walker, Christopher Manring, James L Fisher, Electra D Paskett, Elizabeth Ghias, Jesse J Plascak, Alice Mims, Ann-Kathrin Eisfeld, Jill Buss

Blood (2024) 144 (Supplement 1): 7921.

https://doi.org/10.1182/blood-2024-211563

Published: 2024

Journal Articles

Molecular Features of Acute Myeloid Leukemia in Hispanics: An Analysis from the Marrow Consortium

Blood (2024) 144 (Supplement 1): 3801.

https://doi.org/10.1182/blood-2024-212140

Published: 2024

Journal Articles

GATA2 -Mutated AML: Clinical Outcomes and Spectrum of Infections in Patients Undergoing or Not Allogeneic Stem Cell Transplantation

Blood (2024) 144 (Supplement 1): 7309.

https://doi.org/10.1182/blood-2024-202650

Published: 2024

Journal Articles

A Protein-Coding Circular RNA That Regulates DNA Damage Response in BCR :: ABL -Positive Leukemias

Amog Urs, Dimitrios Papaioannou, Rohan Kulkarni, Chinmayee Goda, Remi Buisson, Deedra Nicolet, Lauren Woodward, Krzysztof Mrózek, Gregory K Behbehani, Sakari Kauppinen, Ann-Kathrin Eisfeld, Iannis Aifantis, Guramrit Singh, Adrienne M. Dorrance, Ramiro Garzon

Blood (2024) 144 (Supplement 1): 954.

https://doi.org/10.1182/blood-2024-208650

Published: 2024

Journal Articles

CRISPR/ Rfx Cas13d Screening Identifies the Long Non-Coding RNA (LncRNA) Nfyc-AS1 As a Molecular Vulnerability in Acute Myeloid Leukemia (AML)

Dimitrios Papaioannou, Giovanni Gambi, Palaniraja Thandapani, Deedra Nicolet, Ziyan Lin, Krzysztof Mrózek, Olha Ivashkiv, Maria Sirenko, Bettina Nadorp, Ann-Kathrin Eisfeld, Aristotelis Tsirigos, Iannis Aifantis

Blood (2024) 144 (Supplement 1): 951.

https://doi.org/10.1182/blood-2024-203707

Published: 2024

Journal Articles

Transcriptomically Defined Acute Myeloid Leukemia, Myelodysplasia-Related (AML-MR) Phenotype Governs Mutation-Based Disease Group Assignment

Lorenz Oelschläger, Deedra Nicolet, Krzysztof Mrózek, Daniel Schnell, Najla Alotaibi, Christopher J. Walker, Alice Mims, James S. Blachly, Bayard L Powell, Jonathan E Kolitz, Eunice S. Wang, Andrew J. Carroll, Lynn van Rosmalen, Bettina Nadorp, Nathan Salomonis, H. Leighton Grimes, Maarten Fornerod, Ann-Kathrin Eisfeld

Blood (2024) 144 (Supplement 1): 641.

https://doi.org/10.1182/blood-2024-210423

Published: 2024

Journal Articles

Real-World Analysis of CPX-351 Induction in Acute Myeloid Leukemia-Myelodysplasia Related (AML-MR): An Updated Analysis from the Marrow Consortium

Daniel T Peters, Deedra Nicolet, Yazan F Madanat, Jesus D Gonzalez-Lugo, Alexander J. Ambinder, Onyee Chan, Michael Jamie Hochman, Najla H. Al Ali, Victoria Klein, Krzysztof Mrózek, Tara L. Lin, Alice Mims, Charles Foucar, Joshua F Zeidner

Blood (2024) 144 (Supplement 1): 324.

https://doi.org/10.1182/blood-2024-193667

Published: 2024

Journal Articles

BRAF -Mutated Acute Myeloid Leukemia (AML) Represents a Prognostically Poor Subgroup Enriched for Myelodysplasia-Related Subtypes and Distinct from Other RAS Pathway Mutant AML

Blood (2024) 144 (Supplement 1): 2921.

https://doi.org/10.1182/blood-2024-210110

Published: 2024

Journal Articles

Characterization of Comparative Clinical Outcomes and Molecular Features of Black Patients with Acute Promyelocytic Leukemia (APL) Reveals Similar Survival and Distinct Genomic Profiles

Blood (2023) 142 (Supplement 1): 389.

https://doi.org/10.1182/blood-2023-182376

Published: 2023

Journal Articles

Patient-Associated Survival Modulators in Adolescent and Young Adult (AYA) Patients (Pts) with Acute Myeloid Leukemia (AML)

Andrea Laganson, Victoria Klein, Deedra Nicolet, Aadarsh Teli, Krzysztof Mrózek, Jacob Wareti, Michael C Walker, Christopher Manring, James L Fisher, Electra D Paskett, Elizabeth Ghias, Alice Mims, Jesse J Plascak, Ann-Kathrin Eisfeld, Jill Buss

Blood (2023) 142 (Supplement 1): 2423.

https://doi.org/10.1182/blood-2023-186423

Published: 2023

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

A randomized study of conventional chemotherapy +/- uproleselan in older adults with Acute Myeloid Leukemia eceiving intensive induction chemotherapy (Alliance A041701)

A multicenter real-world study on response and survival in older patients with acute myeloid leukemia treated with intensive chemotherapy versus VEN/HMA by 2022 and 2024 ELN risk stratifications: An analysis from the MARROW consortium

Characteristics and clinical outcomes of patients (pts) with Acute Myeloid Leukemia (AML) with Mecom rearrangements: An analysis from the MARROW consortium

Defining the clinical characteristics and outcomes of adult patients (pts) with 11q23/KMT2A-rearranged Acute Myeloid Leukemia (AML): An analysis from the MARROW consortium

Accounting for long-term survivors and population-expected survival improves survival outcomes estimation and prediction in older patients with core-binding factor (CBF) Acute Myeloid Leukemia (AML)

Loss of the Y chromosome defines a biologically distinct subtype of Acute Myeloid Leukemia (AML), associated with decreased inflammatory response patterns, and favorable outcomes in young male patients (pts)

Tri-partied analyses define clinical outcomes and molecular features of patients (pts) with acute promyelocytic leukemia (APL)

Treatment responses and survival of newly diagnosed older or unfit patients (pts) with IDH1/2-mutated Acute Myeloid Leukemia (AML): An analysis of the MARROW consortium

Characterization of Sole Loss of the Y Chromosome and Associated Effects on Adaptive Immunity in Adult Male Patients with Acute Myeloid Leukemia (AML)

Real World Outcomes of Patients (Pts) with Acute Myeloid Leukemia, Myelodysplasia-Related (AML-MR) or Therapy-Related AML (t-AML) Receiving Venetoclax-Based Therapies

Impact of Socioeconomic Factors on Survival for Adolescent and Young Adult (AYA) Patients (Pts) with Acute Myeloid Leukemia

Molecular Features of Acute Myeloid Leukemia in Hispanics: An Analysis from the Marrow Consortium

GATA2 -Mutated AML: Clinical Outcomes and Spectrum of Infections in Patients Undergoing or Not Allogeneic Stem Cell Transplantation

A Protein-Coding Circular RNA That Regulates DNA Damage Response in BCR :: ABL -Positive Leukemias

CRISPR/ Rfx Cas13d Screening Identifies the Long Non-Coding RNA (LncRNA) Nfyc-AS1 As a Molecular Vulnerability in Acute Myeloid Leukemia (AML)

Transcriptomically Defined Acute Myeloid Leukemia, Myelodysplasia-Related (AML-MR) Phenotype Governs Mutation-Based Disease Group Assignment

Real-World Analysis of CPX-351 Induction in Acute Myeloid Leukemia-Myelodysplasia Related (AML-MR): An Updated Analysis from the Marrow Consortium

BRAF -Mutated Acute Myeloid Leukemia (AML) Represents a Prognostically Poor Subgroup Enriched for Myelodysplasia-Related Subtypes and Distinct from Other RAS Pathway Mutant AML

Characterization of Comparative Clinical Outcomes and Molecular Features of Black Patients with Acute Promyelocytic Leukemia (APL) Reveals Similar Survival and Distinct Genomic Profiles

Patient-Associated Survival Modulators in Adolescent and Young Adult (AYA) Patients (Pts) with Acute Myeloid Leukemia (AML)

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only